CA2839549A1 - Modulation of tissue transglutaminase activation in disease - Google Patents

Modulation of tissue transglutaminase activation in disease Download PDF

Info

Publication number
CA2839549A1
CA2839549A1 CA2839549A CA2839549A CA2839549A1 CA 2839549 A1 CA2839549 A1 CA 2839549A1 CA 2839549 A CA2839549 A CA 2839549A CA 2839549 A CA2839549 A CA 2839549A CA 2839549 A1 CA2839549 A1 CA 2839549A1
Authority
CA
Canada
Prior art keywords
agent
benzo
compound
imidazole
butyldisulfanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2839549A
Other languages
English (en)
French (fr)
Inventor
Thomas DIRAIMONDO
Xi JIN
Cornelius Kloeck
Chaitan Khosla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2839549A1 publication Critical patent/CA2839549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CA2839549A 2011-06-20 2012-06-19 Modulation of tissue transglutaminase activation in disease Abandoned CA2839549A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499044P 2011-06-20 2011-06-20
US61/499,044 2011-06-20
PCT/US2012/043150 WO2012177640A2 (en) 2011-06-20 2012-06-19 Modulation of tissue transglutaminase activation in disease

Publications (1)

Publication Number Publication Date
CA2839549A1 true CA2839549A1 (en) 2012-12-27

Family

ID=47423169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2839549A Abandoned CA2839549A1 (en) 2011-06-20 2012-06-19 Modulation of tissue transglutaminase activation in disease

Country Status (6)

Country Link
US (2) US20140322278A1 (enExample)
EP (1) EP2721169A4 (enExample)
JP (1) JP2014520147A (enExample)
AU (1) AU2012273105A1 (enExample)
CA (1) CA2839549A1 (enExample)
WO (1) WO2012177640A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116846A1 (en) * 2014-01-30 2015-08-06 The Board Of Trustees Of The Leland Stanford Junior University Modulation of tissue transglutaminase activation in disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116496A1 (en) * 1996-12-06 2004-06-17 Lynn Kirkpatrick Asymmetric Disulfides and methods of using same
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US20040259176A1 (en) * 2003-02-25 2004-12-23 Cerione Richard A. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
AU2012273105A1 (en) 2014-01-09
WO2012177640A2 (en) 2012-12-27
EP2721169A2 (en) 2014-04-23
WO2012177640A3 (en) 2013-03-14
WO2012177640A8 (en) 2014-01-30
EP2721169A4 (en) 2015-06-10
JP2014520147A (ja) 2014-08-21
US20170266198A1 (en) 2017-09-21
US20140322278A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
EP2482815B1 (en) Antiinflammatory 2-oxothiazoles and 2-oxooxazoles
KR101864426B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
AU2002358713B2 (en) Combination of cytochrome P450 dependent protease inhibitors
EA026656B1 (ru) Гетероциклические ингибиторы глютаминазы
US7265093B2 (en) Drug therapy for Celiac Sprue
EP3680232B1 (en) Novel anthranilic acid-based compound, and pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
EP3829520B1 (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
KR20210032439A (ko) 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
JP7744689B2 (ja) 脂質代謝関連疾患の予防又は治療用化合物
KR20150110781A (ko) 항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물
US20090048263A1 (en) Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
AU2018209571A1 (en) Use of cytochrome bc1 complex inhibitor in preparing pharmaceutical composition
EP3381908A1 (en) 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase
TW202214621A (zh) 具有磷脂醯肌醇３－激酶δ和γ的雙重抑制劑活性的雜環化合物及其醫藥用途
WO2018177865A1 (en) Compounds for use as heparanase inhibitors
US20170266198A1 (en) Modulation of tissue transglutaminase activation in disease
AU2004283056A1 (en) Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
WO1999058514A1 (en) (2-acylaminothiazole-4-yl)acetic acid derivatives
JP6768662B2 (ja) Ｎａｄｐｈオキシダーゼに関連する状態の処置に使用するための化合物
WO2023153020A1 (ja) がん細胞増殖抑制剤及びがん細胞増殖抑制効果増強剤
CN105272984B (zh) 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用
WO2016007993A1 (en) Benzene sulfonamide-based inhibitors of sphingosine kinase
RU2801092C2 (ru) Производное галоаллиламинсульфона в качестве ингибиторов лизилоксидазы и их применение
WO2007138705A1 (ja) 発がん抑制剤
JP2777908B2 (ja) 膵炎治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170615

FZDE Discontinued

Effective date: 20191125